Bio Protocol vs Royco V2: DeSci or yield tranches (2026)

Bio Protocol and Royco V2 serve different goals. Bio Protocol connects research collaboration, community funding and a path to commercial products. BIO supports governance through veBIO, launch access through BioXP and liquidity pairing for project tokens. Its focus is early-stage science, so a funded project may never produce a product or revenue.

Royco V2 is built around yield positions rather than research projects. It divides supported yield sources into Senior, Junior and Senior LP tranches. Senior gets base yield with first-loss protection from Junior deposits; Junior accepts first losses in exchange for amplified yield. Senior LP provides the exit pool for Senior positions and earns fees plus a premium.

Choose based on what you want exposure to: Bio Protocol is for DeSci participation, while Royco is for managing yield risk across tranche positions.

Neither protocol publishes a straightforward fee schedule on its homepage. Bio Protocol's launchpad fees, Ignition Sale terms and staking costs are not published, so users should check the terms of each sale and account for normal network gas fees and exchange spreads when buying or bridging BIO. A Bio Protocol case study reports trading fees flowing to a project, but that does not establish the costs or returns a typical user will face.

Royco's documentation includes a governance and fees section, and its app shows market-level figures such as source APY, capacity and Senior LP fees and premium. The yield a user receives depends on how a market splits returns among Senior, Junior and Senior LP. Check the specific market's rates, fees, lockups and exit conditions before depositing.

There is not enough published fee information to declare either protocol cheaper. Compare the exact transaction and market terms before committing funds.

Both protocols carry smart-contract risk, and neither should be treated as risk-free. Bio Protocol has no public audit information listed. Its launchpad involves early-stage project tokens, which may be volatile or illiquid, and many projects may not reach a product or revenue. The protocol's fee and token-sale terms are also not published, making it harder to assess costs in advance.

Royco says it has 20 independent audits, formal verification and 24/7 monitoring by Hypernative. It also describes 3-of-5 council approval and timelocks for critical upgrades. However, some third-party listings show no audits, so users should verify the reports. Royco's risks also depend on the yield source: Junior takes losses first, but severe losses can reach Senior, and stablecoin products can depeg. The council's upgrade powers add a trust assumption.

Review contract and market details carefully, and only commit funds you can afford to lose.

Bio Protocol's standout feature is its end-to-end DeSci model. OpenLabs supports research sharing and collaboration; BIOS AI is described as a research tool; the launchpad funds live projects; and Biofy aims to turn validated science into products, with revenue flowing back to researchers and backers. Specialized science DAOs cover areas such as longevity, women's health, cryopreservation and rare disease. These features make the protocol more relevant to people interested in specific research communities than to users seeking a conventional yield product.

Royco's differentiator is the ability to choose a position with a defined role in a yield market. Its market displays source APY, trailing rate, capacity, liquidity, lockups and withdrawal mechanics. Tranche shares can also be used as collateral, looped for leverage or locked into a fixed rate through an integrated term market. Those options add flexibility, but also complexity.

Bio offers research and funding features; Royco offers a more configurable structure for yield exposure.

Pick Bio Protocol if you want to participate in decentralized science and understand the risks of supporting early-stage projects through tokens. BIO has several stated ecosystem uses, and Bio Protocol's research-to-funding-to-product model gives it a clear purpose. Its listed TVL is about $2.8 million, and its audit information and fee terms are limited, so do not treat its science mission as a substitute for due diligence.

Pick Royco V2 if you are an experienced DeFi user who wants to choose between protected Senior exposure and higher-risk Junior exposure. Its listed TVL is about $7.3 million, but it fell roughly 51% over seven days, and its markets remain exposed to their underlying yield sources. Understand the loss hierarchy, liquidity, lockups and withdrawal mechanics before depositing.

For most users seeking yield, Royco is the more direct match; Bio is the more specific choice for DeSci participation. Neither is a low-risk default.